Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Tyson Foods, Inc. (TSN) Price & Performance

IDEXX Laboratories, Inc.Trade
Tyson Foods, Inc.Trade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Tyson Foods, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Tyson Foods, Inc. trades at $56.59 (market cap $19.85B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.3× Tyson Foods, Inc.'s market cap, and Tyson Foods, Inc. pays a 3.62% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

IDXXTSN
Market Cap
$46.22B$19.85B
Sector
HealthConsumer Staples
52-Week High
$766.68$68.75
52-Week Low
$526.44$50.72
Enterprise Value
$47.12B$27.12B
Dividend Yield
3.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Tyson Foods, Inc.

Tyson Foods (TSN) trades at $55.97, down 2.08% on the day, amid a bearish technical signal and mixed quarterly performance. Recent Q3 2026 earnings of $0.99 per share beat estimates, but revenue and volumes declined year-over-year. The company maintains a strong cash flow from operations of $2.16B in 2025, though net income margins are thin at 1.03%. Analyst consensus is a Buy with a $68.50 price target, highlighting a potential 22% upside from current levels.

The outlook for TSN is cautiously optimistic, with valuation metrics like P/S of 0.36 and EV/EBITDA of 10.38 suggesting potential undervaluation. Key risks include persistent losses in the beef segment due to high cattle costs and competitive pressures. Investment opportunity lies in the strength of chicken and prepared foods divisions, supported by a stable dividend yield. Monitoring Q3 2026 earnings release and beef margin normalization is critical for future performance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX

About Tyson Foods, Inc.

Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.

Read more on TSN